Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Dosage Regimen: Individualization
Peripheral Artery Disease III: Interprofessional Care
Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration
Coronary Artery Disease V: Interprofessional Care
Dosage Regimen: Fixed Dose
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Updated: Apr 12, 2026

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System
Published on: December 7, 2012
Martine Gilard1, Marie Claude Morice2
1Département de Cardiologie, Brest-University, Brest, France.
No abstract available in PubMed .